SEC Form SC 13G filed by Lyell Immunopharma Inc.

10/31/24 6:00:17 PM ET

$LYEL

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LYEL alert in real time by email

SC 13G 1 tm2427216d1_sc13g.htm SC 13G

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d)
AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. ___________)*

Lyell Immunopharma, Inc.

(Name of Issuer)

Common Stock, par value $0.0001

(Title of Class of Securities)

55083R104

(CUSIP Number)

October 25, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)

Page 1 of 10

Exhibit Index on Page 9

CUSIP # 55083R104

Page 2 of 16

1	NAME OF REPORTING PERSONS	Foresite Capital Fund IV, L.P. (“FCF IV”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a)         ¨         (b)         x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 8,325,000 shares, except that Foresite Capital Management IV, LLC (“FCM IV”), the general partner of FCF IV, may be deemed to have sole power to vote these shares, and James Tananbaum (“Tananbaum”), the managing member of FCM IV, may be deemed to have sole power to vote these shares.
	6	SHARED VOTING POWER See response to row 5.
	7	SOLE DISPOSITIVE POWER 8,325,000 shares, except that FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares.
	8	SHARED DISPOSITIVE POWER See response to row 7.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	8,325,000
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	3.2%¹
12	TYPE OF REPORTING PERSON	PN

1 This percentage is calculated based upon 256,593,235 Common Stock outstanding of Lyell Immunopharma, Inc. (the “Issuer”) as of October 23, 2024, as set forth in Exhibit 2.1 to the Issuer’s Form 8-K filed with the Securities and Exchange Commission on October 24, 2024.

CUSIP # 55083R104

Page 3 of 16

1	NAME OF REPORTING PERSONS	Foresite Capital Management IV, LLC (“FCM IV”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a)         ¨         (b)         x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 8,325,000 shares, all of which are directly owned by FCF IV. FCM IV, the general partner of FCF IV, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to vote these shares.
	6	SHARED VOTING POWER See response to row 5.
	7	SOLE DISPOSITIVE POWER 8,325,000 shares, all of which are directly owned by FCF IV. FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares.
	8	SHARED DISPOSITIVE POWER See response to row 7.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	8,325,000
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	3.2%²
12	TYPE OF REPORTING PERSON	OO

2 This percentage is calculated based upon 256,593,235 Common Stock outstanding of the Issuer as of October 23, 2024, as set forth in Exhibit 2.1 to the Issuer’s Form 8-K filed with the Securities and Exchange Commission on October 24, 2024.

CUSIP # 55083R104

Page 4 of 16

1	NAME OF REPORTING PERSONS	Foresite Capital Fund V, L.P. (“FCF V”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a)         ¨         (b)         x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 3,907,500 shares, except that Foresite Capital Management V, LLC (“FCM V”), the general partner of FCF V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares.
	6	SHARED VOTING POWER See response to row 5.
	7	SOLE DISPOSITIVE POWER 3,907,500 shares, except that FCM V, the general partner of FCF V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares.
	8	SHARED DISPOSITIVE POWER See response to row 7.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	3,907,500
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	1.5%³
12	TYPE OF REPORTING PERSON	PN

3 This percentage is calculated based upon 256,593,235 Common Stock outstanding of the Issuer as of October 23, 2024, as set forth in Exhibit 2.1 to the Issuer’s Form 8-K filed with the Securities and Exchange Commission on October 24, 2024.

CUSIP # 55083R104

Page 5 of 16

1	NAME OF REPORTING PERSONS	Foresite Capital Management V, LLC (“FCM V”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a)         ¨         (b)         x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 3,907,500 shares, all of which are directly owned by FCF V. FCM V, the general partner of FCF V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to vote these shares.
	6	SHARED VOTING POWER See response to row 5.
	7	SOLE DISPOSITIVE POWER 3,907,500 shares, except that FCM V, the general partner of FCF V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM V, may be deemed to have sole power to dispose of these shares.
	8	SHARED DISPOSITIVE POWER See response to row 7.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	3,907,500
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	1.5%⁴
12	TYPE OF REPORTING PERSON	OO

4 This percentage is calculated based upon 256,593,235 Common Stock outstanding of the Issuer as of October 23, 2024, as set forth in Exhibit 2.1 to the Issuer’s Form 8-K filed with the Securities and Exchange Commission on October 24, 2024.

CUSIP # 55083R104

Page 6 of 16

1	NAME OF REPORTING PERSONS	Foresite Capital Opportunity Fund V, L.P. (“FCF Opp V”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a)         ¨         (b)         x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 1,451,358 shares, except that Foresite Capital Opportunity Management V, LLC (“FCM Opp V”), the general partner of FCF Opp V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to vote these shares.
	6	SHARED VOTING POWER See response to row 5.
	7	SOLE DISPOSITIVE POWER 1,451,358 shares, except that FCM Opp V, the general partner of FCF Opp V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to dispose of these shares.
	8	SHARED DISPOSITIVE POWER See response to row 7.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	1,451,358
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	0.6%⁵
12	TYPE OF REPORTING PERSON	PN

5 This percentage is calculated based upon 256,593,235 Common Stock outstanding of the Issuer as of October 23, 2024, as set forth in Exhibit 2.1 to the Issuer’s Form 8-K filed with the Securities and Exchange Commission on October 24, 2024.

CUSIP # 55083R104

Page 7 of 16

1	NAME OF REPORTING PERSONS	Foresite Capital Opportunity Management V, LLC (“FCM Opp V”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a)         ¨         (b)         x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 1,451,358 shares, all of which are directly owned by FCF Opp V. FCM Opp V, the general partner of FCF Opp V, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to vote these shares.
	6	SHARED VOTING POWER See response to row 5.
	7	SOLE DISPOSITIVE POWER 1,451,358 shares, all of which are directly owned by FCF Opp V. FCM Opp V, the general partner of FCF Opp V, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM Opp V, may be deemed to have sole power to dispose of these shares.
	8	SHARED DISPOSITIVE POWER See response to row 7.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	1,451,358
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	0.6%⁶
12	TYPE OF REPORTING PERSON	OO

6 This percentage is calculated based upon 256,593,235 Common Stock outstanding of the Issuer as of October 23, 2024, as set forth in Exhibit 2.1 to the Issuer’s Form 8-K filed with the Securities and Exchange Commission on October 24, 2024.

CUSIP # 55083R104

Page 8 of 16

1	NAME OF REPORTING PERSONS	James Tananbaum (“Tananbaum”)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a)         ¨         (b)         x
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 13,683,858 shares, all of which 8,325,000 shares are directly owned by FCF IV, 3,907,500 shares are directly owned by FCF V and 1,451,358 shares are directly owned by FCF Opp V. Tananbaum is the managing member of each of FCM IV, which is the general partner of FCF IV, FCM V, which is the general partner of FCF V and FCM Opp V, which is the general partner of FCF Opp V. Tananbaum may be deemed to have sole power to vote these shares.
	6	SHARED VOTING POWER See response to row 5.
	7	SOLE DISPOSITIVE POWER 13,683,858 shares, all of which 8,325,000 shares are directly owned by FCF IV, 3,907,500 shares are directly owned by FCF V and 1,451,358 shares are directly owned by FCF Opp V. Tananbaum is the managing member of each of FCM IV, which is the general partner of FCF IV, FCM V, which is the general partner of FCF V and FCM Opp V, which is the general partner of FCF Opp V. Tananbaum may be deemed to have sole power to dispose of these shares.
	8	SHARED DISPOSITIVE POWER See response to row 7.

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	13,683,858
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	5.3%⁷
12	TYPE OF REPORTING PERSON	IN

7 This percentage is calculated based upon 256,593,235 Common Stock outstanding of the Issuer as of October 23, 2024, as set forth in Exhibit 2.1 to the Issuer’s Form 8-K filed with the Securities and Exchange Commission on October 24, 2024.

CUSIP # 55083R104

Page 9 of 16

ITEM 1(A).

NAME OF ISSUER

Lyell Immunopharma, Inc. (the “Issuer”)

ITEM 1(B).

ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

201 Haskins Way

South San Francisco, California 94080

ITEM 2(A).

NAME OF PERSONS FILING

This Schedule is filed by Foresite Capital Fund IV, L.P., a Delaware limited partnership (“FCF IV”), Foresite Capital Management IV, LLC, a Delaware limited liability company (“FCM IV”), Foresite Capital Fund V, L.P., a Delaware limited partnership (“FCF V”), Foresite Capital Management V, LLC, a Delaware limited liability company (“FCM V”), Foresite Capital Opportunity Fund V, L.P., a Delaware limited partnership (“FCF Opp V”), Foresite Capital Opportunity Management V, LLC, a Delaware limited liability company (“FCM Opp V”) and James Tananbaum. The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

ITEM 2(B).

ADDRESS OF PRINCIPAL OFFICE

The address for each of the Reporting Persons is:

c/o Foresite Capital Management

900 Larkspur Landing Circle, Suite 150
Larkspur, CA 94939

ITEM 2(C).

CITIZENSHIP

See Row 4 of cover page for each Reporting Person.

ITEM 2(D).

TITLE OF CLASS OF SECURITIES

Common Stock, par value $0.0001

ITEM 2(E)

CUSIP NUMBER

55083R104

ITEM 3.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

ITEM 4.

OWNERSHIP

The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this Statement is provided as of October 25, 2024:

CUSIP # 55083R104

Page 10 of 16

(a)

Amount beneficially owned:

See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class:

See Row 11 of cover page for each Reporting Person.

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote:

See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote:

See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of:

See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of:

See Row 8 of cover page for each Reporting Person.

ITEM 5.

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Not applicable.

ITEM 6.

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Under certain circumstances set forth in the limited partnership agreements of FCF IV, FCF V and FCF Opp V and the limited liability company agreements of FCM IV, FCM V and FCM Opp V, the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.

ITEM 7.

IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable.

ITEM 8.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not applicable

ITEM 9.

NOTICE OF DISSOLUTION OF GROUP.

Not applicable

CUSIP # 55083R104

Page 11 of 16

ITEM 10.

CERTIFICATION.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

CUSIP # 55083R104

Page 12 of 16

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 31, 2024

		FORESITE CAPITAL FUND IV, L.P.

		By:	FORESITE CAPITAL MANAGEMENT IV, LLC
		Its:	General Partner

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member


		FORESITE CAPITAL MANAGEMENT IV, LLC

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member


		FORESITE CAPITAL FUND V, L.P.

		By:	FORESITE CAPITAL MANAGEMENT V, LLC
		Its:	General Partner

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member


		FORESITE CAPITAL MANAGEMENT V, LLC

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member


		FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

		By:	FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC
		Its:	General Partner

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member

CUSIP # 55083R104

Page 13 of 16

		FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member


		JAMES TANANBAUM

		By:	/s/ James Tananbaum
		Name:	James Tananbaum

CUSIP # 55083R104

Page 14 of 16

EXHIBIT INDEX

		Found on Sequentially
Exhibit		Numbered Page
Exhibit A: Agreement of Joint Filing		10

CUSIP # 55083R104

Page 15 of 16

exhibit A

Agreement of Joint Filing

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of the Issuer shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

Date: October 31, 2024

		FORESITE CAPITAL FUND IV, L.P.

		By:	FORESITE CAPITAL MANAGEMENT IV, LLC
		Its:	General Partner

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member


		FORESITE CAPITAL MANAGEMENT IV, LLC

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member


		FORESITE CAPITAL FUND V, L.P.

		By:	FORESITE CAPITAL MANAGEMENT V, LLC
		Its:	General Partner

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member


		FORESITE CAPITAL MANAGEMENT V, LLC

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member


		FORESITE CAPITAL OPPORTUNITY FUND V, L.P.

		By:	FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC
		Its:	General Partner

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member

CUSIP # 55083R104

Page 16 of 16

		FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLC

		By:	/s/ James Tananbaum
		Name:	James Tananbaum
		Title:	Managing Member


		JAMES TANANBAUM

		By:	/s/ James Tananbaum
		Name:	James Tananbaum

Get the next $LYEL alert in real time by email

Date	Price Target	Rating	Analyst
10/30/2024	$6.00 → $1.00	Buy → Underperform	BofA Securities
6/27/2024	$6.00 → $1.00	Buy → Neutral	H.C. Wainwright
8/28/2023	$15.00 → $5.00	Overweight → Neutral	JP Morgan
11/14/2022	$15.00 → $7.00	Overweight → Equal-Weight	Morgan Stanley
11/11/2022	$13.00 → $7.00	Buy → Neutral	Goldman
10/17/2022	$12.00	Buy	H.C. Wainwright
1/6/2022	$25.00 → $20.00	Overweight	Morgan Stanley
7/12/2021	$25.00	Buy	BofA Securities

SEC Form SC 13G filed by Lyell Immunopharma Inc.

Chat with this insight

Recent Analyst Ratings for $LYEL

$LYEL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Klausner Richard

SEC Form 4 filed by Director Rieflin William Jl

SEC Form 4 filed by Director Friedman Cathy

$LYEL SEC Filings

SEC Form 8-K filed by Lyell Immunopharma Inc.

SEC Form 8-K filed by Lyell Immunopharma Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Lyell Immunopharma Inc.

$LYEL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Lyell Immunopharma Inc.

Amendment: SEC Form SC 13G/A filed by Lyell Immunopharma Inc.

SEC Form SC 13G filed by Lyell Immunopharma Inc.

$LYEL Press Releases

Fastest customizable press release news feed in the world

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

$LYEL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Brawley Otis W bought $19,958 worth of shares (35,640 units at $0.56) (SEC Form 4)

Director Ramachandra Sumant bought $115,220 worth of shares (200,000 units at $0.58) (SEC Form 4)

Director Klausner Richard bought $94,942 worth of shares (158,000 units at $0.60) (SEC Form 4)

$LYEL Leadership Updates

Live Leadership Updates

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

$LYEL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lyell Immunopharma downgraded by BofA Securities with a new price target

Lyell Immunopharma downgraded by H.C. Wainwright with a new price target

Lyell Immunopharma downgraded by JP Morgan with a new price target

$LYEL Financials

Live finance-specific insights

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Recent Analyst Ratings for
$LYEL

$LYEL
Insider Trading

$LYEL
SEC Filings

$LYEL
Large Ownership Changes

$LYEL
Press Releases

$LYEL
Insider Purchases

$LYEL
Leadership Updates

$LYEL
Analyst Ratings

$LYEL
Financials